Documents

Strong FY26 growth with FDA-cleared CT:VQ™, 21% revenue rise, and $278M cash for expansion.

CT-based lung imaging technology is rapidly replacing nuclear scans, driving strong growth and margins.

CLEAR study, European expansion, and SimonMed deal drive growth and market opportunity.

CT:VQ drives improved lung therapy outcomes, workflow efficiency, and rapid clinical adoption.

CT:VQ™ adoption accelerates globally, driving SaaS growth and robust financial performance.

CT-based imaging is set to replace nuclear VQ scans, driving rapid growth and market expansion.

FDA clearance, SaaS growth, and $150M raise drive global expansion amid audit qualification.

FDA-cleared CT:VQ™ launches with rapid adoption, 51% site growth, and $33.5M cash on hand.

CT:VQ is set for rapid U.S. adoption, backed by Philips and strong hospital demand.

FDA clearance, Philips deal, and SaaS growth drive revenue up 56%, but losses persist.

CTVQ aims to capture the entire US nuclear VQ market with validated, accessible CT-based imaging.

Record revenue growth, cost savings, and new contracts drive 4DMedical's global expansion.

Strong revenue growth, cost reduction, and major U.S. partnerships drive positive outlook.

Rapid growth and new CT-based products set the stage for major disruption in lung diagnostics.

Q1 revenue up 366% and Philips deal set 4DMedical for U.S. growth and regulatory advances.

Revenue up 422%, Imbio acquired, Philips US deal signed, but $36m net loss recorded.

FY2024 revenue up 422% to $3.8m, with strong cash and U.S. Medicare reimbursement fueling growth.